Skip to content

Vitamin D for Improving Metabolic Control and Depressive Symptoms

Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01185574
Enrollment
50
Registered
2010-08-20
Start date
2009-10-31
Completion date
2012-05-31
Last updated
2013-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Symptoms, Diabetes

Brief summary

This study will examine whether weekly vitamin D supplementation in women with significant depressive symptoms and diabetes will exhibit improved mood and metabolic control. If supplementation with Vitamin D is beneficial, it will be a simple and cost-effective method for treatment. Women will be targeted since they have greater depression and worse metabolic control than men with diabetes.

Interventions

DIETARY_SUPPLEMENTVitamin D supplementation

Vitamin D2 50,000 IU will be administered once a week for six months.

Sponsors

Loyola University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Women aged 18 and older 2. medically stable type 2 diabetes with HBA1c \<9%. 3. significantly elevated depressive symptoms as measured by a score greater than or equal to 14 using the Center for Epidemiologic Studies Depression Tool (CES-D.

Exclusion criteria

1. vitamin D levels of 32 ng/dl or greater 2. malabsorption problems (e.g., crohn's disease, celiac sprue) 3. hypercalcemia-level greater than 10.5 mg/dl 4. Severe complications of diabetes (amputation, blindness, or renal problems) 5) Women with low thyroid function 6\) active suicidal ideation, a history of bipolar depression, psychotic disorders, and current alcohol or substance disorders. Active treatment for depression (e.g., antidepressant therapy) will not be

Design outcomes

Primary

MeasureTime frame
Metabolic control6 months

Secondary

MeasureTime frame
depressive symptoms6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026